Skylark Bio

#CNS #Gene therapy #Skylark Bio

Skylark Bio expands gene therapy pipeline into CNS

Skylark Bio has revealed it is expanding its pipeline with SKY-AS, a differentiated gene therapy candidate designed to restore UBE3A expression in individuals with Angelman syndrome (AS).   SKY-AS represents the company’s first central nervous system (CNS) development programme and expands Skylark’s portfolio of precision, locally delivered… Read More

#News

#Gene therapy #Hearing Loss #Phase I trial #Skylark Bio

Skylark initiates trial of gene therapy for hearing loss

Skylark Bio has dosed the first patient in the SONIX Phase I/II clinical trial evaluating SKY-GJB2, its investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss. “Dosing the first patient in SONIX brings us one step closer to a future where children born with genetic hearing loss have new… Read More

#News